Agentix (AGTX) Cash from Investing Activities (2013 - 2017)

Agentix's (AGTX) quarterly Cash from Investing Activities came in at $193.0 in Q3 2017, down 33.68% on a QoQ basis from $291.0 in Q2 2017.

Agentix (AGTX) Cash from Investing Activities (2013 - 2017) Analysis & Trends

Agentix (AGTX) has 3 years of Cash from Investing Activities data on file, last reported at $193.0 in Q3 2017.

Quarterly Cash from Investing Activities changed N/A year-over-year to $193.0 in Q3 2017, while the trailing twelve-month figure through May 2021 was $193.0 (changed N/A YoY) and the FY2020 annual result came in at $17.0, changed N/A from the prior year.
Cash from Investing Activities declined to $193.0 in Q3 2017, from $291.0 in the prior quarter.
In the past five years, Cash from Investing Activities ranged from a high of $291.0 in Q2 2017 to a low of -$10000.0 in Q4 2016.
A 3-year average of -$3515.5 and a median of -$2176.5 in 2013 frame the typical range for Cash from Investing Activities.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Investing Activities (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-45.80 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-92.70 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	329.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-49.35 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-363.46 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-3.17 Bn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	24.51 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-229.72 Mn
10	Agentix	801,339.00	801,301.00	-	-

Download Data